Description

Tiprelestat is a potent human neutrophil elastase inhibitor. Tiprelestat has antimicrobial and anti-inflammatory activities. Tiprelestat can be used in the research of inflammation/immune disease[1].—COVID-19-immunoregulation–C254H416N72O75S10—-[1]Wang J, et al. Elafin inhibits obesity, hyperglycemia, and liver steatosis in high-fat diet-treated male mice. Sci Rep. 2020 Jul 30;10(1):12785. |[2]Alejandre Alcazar MA, et al. Elafin Treatment Rescues EGFR-Klf4 Signaling and Lung Cell Survival in Ventilated Newborn Mice. Am J Respir Cell Mol Biol. 2018 Nov;59(5):623-634. |[3]Bellemare A, et al. Human pre-elafin inhibits a Pseudomonas aeruginosa-secreted peptidase and prevents its proliferation in complex media. Antimicrob Agents Chemother. 2008 Feb;52(2):483-90. |[4]Butler MW, et al. Elafin prevents lipopolysaccharide-induced AP-1 and NF-kappaB activation via an effect on the ubiquitin-proteasome pathway. J Biol Chem. 2006 Nov 17;281(46):34730-5.|[5]Nickel NP, et al. Elafin Reverses Pulmonary Hypertension via Caveolin-1-Dependent Bone Morphogenetic Protein Signaling. Am J Respir Crit Care Med. 2015 Jun 1;191(11):1273-86. –820211-82-3–5999.09—-[Tiprelestat]–Infection; Inflammation/Immunology–10 mM in DMSO–Elastase—-Metabolic Enzyme/Protease–Peptides